IL-13Rα2及IL-13在胶质瘤发生发展及治疗中的研究进展  

Research progress of IL-13Rα2 and IL-13 in the development and treatment of glioma

作　　者：邹存义 吴安华[1] 

机构地区：[1]中国医科大学附属第一医院神经外科,辽宁沈阳110001

出　　处：《转化医学电子杂志》2017年第7期28-32,共5页E-Journal of Translational Medicine

基　　金：国家自然科学基金资助项目(81172409;81472360)

摘　　要：IL-13为活化Th2细胞分泌的多功能细胞因子,在炎症性疾病中具有重要作用.其高亲和力受体IL-13Rα2,作为诱导受体在恶性胶质瘤中高表达,与肿瘤不良预后相关.胶质瘤细胞中,IL-13Rα2与IL-13结合通过其胞内尾端与IL-4Rα相互作用,抑制IL-4R介导的STAT6信号通路,进而促进肿瘤细胞的侵袭转移与增殖,抑制肿瘤细胞凋亡.由于IL-13Rα2在胶质瘤中特异性高表达,使其成为胶质瘤靶向治疗和免疫治疗的理想位点,且已取得了突破性进展.IL-13Rα2与IL-13在胶质瘤中作用及机制的进一步明确,有利于为胶质瘤治疗提供充分的依据.IL-13 is a muhifunctional cytokine secreted by acti- vated Th2 ceils and plays an important role in inflammatory disea- ses. IL-13Rα2, a high-affinity decoy receptor, is highly expressed in malignant g]ioma and is associated with poor prognosis. In glio- ma cells, IL-13Rα2 combined with IL-13 interacts with IL-4Rα through the end domain of the intracelIular to inhibit STAT6 signa- ling pathway mediated by IL-4R. It can promote the invasion, metastasis and proliferation, and inhibit the apoptosis of tumor cells. Because of the high expression of IL-13Rα2 in glioma, it has become an ideal target for targeted therapy and immunotherapy of glioma. The role and mechanism of IL-13Rα2 and IL-13 in glioma are further clarified, which is helpful to improve the treat- merit of glioma.

关 键 词：IL-13RΑ2 IL-13 胶质瘤 治疗 

分 类 号：R739.41[医药卫生—肿瘤]